Profound medical announces category 1 cpt codes proposed cy2025 rule for tulsa to treat prostate diseases

Toronto, july 11, 2024 (globe newswire) -- profound medical corp. (nasdaq:prof; tsx:prn) (“profound” or the “company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that u.s. centers for medicare and medicaid services (cms) has issued its proposed rules establishing, for the first time, a category 1 cpt code for the transurethral ultrasound ablation (“tulsa”) procedure, effective january 1, 2025.
CPT Ratings Summary
CPT Quant Ranking